A multi-centre, randomized, double blind, placebo-controlled, parallel group study to investigate efficacy and safety of ONO-2506PO compared to placebo, in the presence of riluzole, to patients diagnosed with amyotrophic lateral sclerosis (ALS), who have had onset of muscle weakness within 14 months of randomization.
Latest Information Update: 05 Oct 2021
At a glance
- Drugs Arundic acid (Primary) ; Riluzole
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- Sponsors Ono Pharmaceutical
- 11 Dec 2008 Actual trial completion date identified as December 2008 from ClinicalTrials.gov.
- 11 Dec 2008 Actual trial completion date identified as December 2008 from ClinicalTrials.gov.
- 11 Dec 2008 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov.